Zobrazeno 1 - 5
of 5
pro vyhledávání: '"David Arpon"'
Autor:
Clara Liu Chung Ming, Kimberly Sesperez, Eitan Ben-Sefer, David Arpon, Kristine McGrath, Lana McClements, Carmine Gentile
Publikováno v:
Cells, Vol 10, Iss 4, p 899 (2021)
Preeclampsia is a multifactorial cardiovascular disorder diagnosed after 20 weeks of gestation, and is the leading cause of death for both mothers and babies in pregnancy. The pathophysiology remains poorly understood due to the variability and unpre
Externí odkaz:
https://doaj.org/article/7c3ae80842ca4fbfb0949424a80a36b6
Autor:
Yavar Shiravand, Kenneth J. O'Byrne, Payar Radfar, Hamid Sadeghi Rad, Habib Sadeghi Rad, Majid Ebrahimi Warkiani, David Arpon, Arutha Kulasinghe
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 159
Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survival rate ~20%. Immunotherapies have demonstrated long-term and durable responses in NSCLC patients, although they appear to be effective in only a sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb740a2d713daf9f8f8d9b093f67f849
https://pubmed.ncbi.nlm.nih.gov/34304051
https://pubmed.ncbi.nlm.nih.gov/34304051
Autor:
Clare Gould, David Arpon, Frank Vari, Simone Birch, Mark Hertzberg, Maher K. Gandhi, Annette Hernandez, Dipti Talaulikar, Qingyan Cui, Erica Han, Colm Keane, Robert Bird, Josh Tobin, Sanjiv Jain, Donna Cross
Publikováno v:
Blood. 131(16)
Much focus has been on the interaction of programmed cell death ligand 1 (PD-L1) on malignant B cells with programmed cell death 1 (PD-1) on effector T cells in inhibiting antilymphoma immunity. We sought to establish the contribution of natural kill
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174596090a8a42d0390c2b7511e879d7
https://pubmed.ncbi.nlm.nih.gov/29674350
https://pubmed.ncbi.nlm.nih.gov/29674350
Publikováno v:
British Journal of Clinical Pharmacology. 78:274-281
The issue of tailored dosing adjusted according to a range of patient-specific factors other than bodyweight or body surface area is of large and increasing clinical and financial concern. Even if it is known that dosing alterations are likely to be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0067242edc4fcec2e401dc02b664f6d8
https://doi.org/10.1111/bcp.12318
https://doi.org/10.1111/bcp.12318
Autor:
Colm Keane, David Arpon, Josh Tobin, Frank Vari, Mark Hertzberg, Annette Hernandez, Erica Han, Donna Cross, Marlene Self, Maher K. Gandhi, Robert Bird
Publikováno v:
Blood. 128:918-918
PD-L1/PD-L2 are immunomodulatory molecules that engage with the PD-1 receptor on immune effector T and NK-cells to inhibit anti-lymphoma immunity. PD-1/PD-L1/PD-L2 axis molecules are prognostic in Hodgkin Lymphoma (HL, Roemer et al J Clin Oncol 2016)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4ba02ce30d5a09a1769866aa5818ada
https://doi.org/10.1182/blood.v128.22.918.918
https://doi.org/10.1182/blood.v128.22.918.918